THE
BLADDER CANCER
COMPANY

Photocure ASA - Share option grant

Oslo, Norway, 14 July 2026 - Photocure ASA (the "Company") (OSE: PHO) has granted share options to employees.

A total of 223.750 share options, equal to 0,825% of total shares issued in the Company, were granted to employees at an exercise price at NOK 66.20. The exercise price is equal to the weighted average share price 30 trading days before day of grant with an additional premium of 10% on top of the calculated average price.

The options are granted with terms as set out in Photocure's long term incentive program and described in the annual report 2025 (note 6).

For further information, please contact:

Priyam Shah
Vice President Investor Relations
Tel : +17176815072
Email: priyam.shah@photocure.com

About Photocure ASA
Photocure is a commercial diagnostic company with global reach, committed to driving progress in uro-oncology precision diagnostics, delivering meaningful advances for patients with urological cancers. Our unique core technology has led to better health outcomes for patients worldwide. The company aims to provide an array of transformative solutions that help physicians with timely diagnostic information, to inform more personalized decisions on how best to manage each individual patient. Photocure is headquartered in Oslo, Norway and listed on the Oslo Stock Exchange (OSE: PHO). For more information, please visit www.photocure.com/news

This information is subject to the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act.